Highlands Oncology Group.

Clinical research site in Springdale, Arkansas · 3901 PARKWAY CIR, SPRINGDALE, AR 72762-6362 · (479) 587-1700 · Website

Part of Highlands Oncology Group

As of July 2026, 41 paid clinical trials are recruiting at Highlands Oncology Group. in Springdale, Arkansas. Active studies at this site cover conditions such as Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Highlands Oncology Group. (41)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Advanced Non-Small Cell Lung Cancer

186 locations incl. Bullhead City

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222566·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

48 locations incl. Tucson

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for Breast Neoplasms

58 locations incl. Springdale

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07173751·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

133 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

for Metastatic Castration-Resistant Prostate Cancer

44 locations incl. Chandler

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT06629779·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

86 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

39 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

45 locations incl. Little Rock

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

37 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

for Melanoma

31 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05355701·Phase 1·Recruiting·Listed May 2022

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

30 locations incl. Springdale

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

11 locations incl. Springdale

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07518186·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

21 locations incl. Springdale

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for Hematologic Malignancies

7 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04728893·Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

for NSCLC Stage IV

19 locations incl. Springdale

Sponsor: ImmunityBio, Inc.

Sex: All·Age: 18 - 90

Code: NCT06745908·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for Advanced Solid Tumor

19 locations incl. Birmingham

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT06635785·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

for Solid Tumors (Phase 1)

3 locations incl. Springdale

Sponsor: Adcendo ApS

Sex: All·Age: 18+

Code: NCT07362888·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

for Platinum-resistant Ovarian Cancer

7 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: Female·Age: 18+

Code: NCT07226427·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

for Malignant Melanoma

5 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06961006·Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for Leukemia, Lymphocytic, Chronic, B-Cell

5 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05947851·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

for Advanced Clear Cell Renal Cell Carcinoma

41 locations incl. Fayetteville

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT07383441·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

for Advanced Endometrial Carcinoma

228 locations incl. Virginia

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

449 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for Advanced Lung Non-Small Cell Carcinoma

266 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 70+

Code: NCT06096844·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for Muscle Invasive Bladder Urothelial Carcinoma

148 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07061964·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

for Locally Advanced Pancreatic Adenocarcinoma

272 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06998940·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

250 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

127 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

645 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

915 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

83 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Showing the 40 most relevant of 41 recruiting trials at this site. Browse all with filters →

More research sites in Springdale

Highlands Oncology Group (40 trials)
Highlands Oncology Group, PA (8 trials)
Retina Partners of Northwest Arkansas, PLLC (3 trials)
Highlands Oncology Group - Springdale (3 trials)
Adverum Clinical (1 trial)
Arkansas Children's Northwest (1 trial)
Community Clinic (1 trial)
Highlands Oncology Group-Research Department (1 trial)
Local Institution - 0686 (1 trial)
Rouse Family Medical Clinic (1 trial)

Explore more

Paid clinical trials in Springdale, AR · Arkansas clinical trials